Below is a concise market brief for the Psoriasis Drugs Market with (1) a market-size anchor, (2) a short list of the leading companies and public values I can find (drug-level sales where reported), and (3) the sections you requested (recent developments, drivers, restraints, regions, trends, use cases, challenges, opportunities, key expansion factors). I cite the primary sources for the most important factual claims so you can follow up.

This versatile research report is presenting crucial details on market relevant information, harping on ample minute details encompassing a multi-dimensional market that collectively maneuver growth in the global Psoriasis Drugs market.

This holistic report presented by the report is also determined to cater to all the market specific information and a take on business analysis and key growth steering best industry practices that optimize million-dollar opportunities amidst staggering competition in Psoriasis Drugs market.

Read complete report at: https://www.thebrainyinsights.com/report/psoriasis-drugs-market-12599

Market snapshot

• Global market (2024 estimate): ~USD 21.12 billion (2024); projected to nearly double to ~USD 39.11 billion by 2030 (CAGR ~10.9%) under one widely-used forecast. 

Key companies & public values (representative drug sales / anchors)

Note: Most large pharma groups report psoriasis drugs inside broader immunology or specialty care segments. Below I list leading psoriasis medicines and the drug-level sales figures publicized for 2024 (or latest reported period).

• AbbVie — Skyrizi (risankizumab) — Skyrizi: reported blockbuster-level sales (2024); published industry tallies place Skyrizi at ~$11.7 billion (2024) and AbbVie reports rapid Skyrizi growth in its investor releases.

• Johnson & Johnson (Janssen) — Stelara (ustekinumab) — Stelara: reported ≈ $10.4 billion (2024) in J&J product sales reporting. (Stelara has faced biosimilar pressure in 2024–2025, affecting growth trajectories in some markets.)

• Novartis — Cosentyx (secukinumab) — Cosentyx: reported product sales USD 6,141 million (2024) in Novartis product-sales tables. 

• Eli Lilly — Taltz (ixekizumab) — Taltz: reported ~USD 3.2 billion (2024) (company reporting / industry summaries). 

• Amgen / Celgene-origin products — Otezla (apremilast) — Otezla remains an important oral option; company reports show quarterly/full-year sales in the low-single-billion USD range and year-over-year declines in recent quarters (Otezla Q4 2024: $624M). Use Amgen reports / GlobalData for time-series.

Other important companies/products referenced frequently in market reports: UCB (Bimzelx / bimekizumab), Janssen (Tremfya / guselkumab), Bristol Myers Squibb (Sotyktu / deucravacitinib), and a range of smaller/innovator companies developing new small molecules or biologics. Many of these newer entrants are gaining share in specific niches (IL-23, IL-17, TYK2 inhibitors). 

Recent developments (2023–2025)

• Shift to IL-23 and IL-17 biologics that deliver high clearance rates and long dosing intervals — these brands have been the fastest-growing class and explain much of the recent market expansion (Skyrizi, Tremfya, Cosentyx, Taltz).

• Patent expiries / biosimilars are reshaping some segments (notably for older biologics), while newer strong-selling biologics continue to capture share.

• Emergence of oral targeted agents (TYK2 inhibitors) as a meaningful new class (e.g., deucravacitinib) that competes with both biologics and older orals.

Drivers

• Rising prevalence and diagnosis of psoriasis globally, plus growing treatment uptake for moderate-to-severe disease.

• Superior efficacy & convenience of newer biologics (IL-23/IL-17) leading to switching from older treatments and driving per-patient drug spend. 

• Greater access and reimbursement in emerging markets as biologics become more available through pricing strategies / local manufacturing / payer coverage.

Restraints

• High cost of biologics limits access in some regions and increases payer scrutiny; price pressure from biosimilars moderates market growth in older product classes. 

• Safety and long-term data requirements — some payers and clinicians remain cautious and require long-term outcome data for newly launched agents. 

Regional segmentation (high level)

• North America — largest market by spend (high per-patient drug costs, mature biologic uptake).

• Europe — significant uptake, but price and biosimilar dynamics differ by country; regional regulation affects speed of new launches.

• Asia-Pacific — fastest volume growth (increasing diagnosis, expanding access), but per-capita spend remains lower; strong opportunity for growth if pricing/access improves.

Emerging trends

• Oral small-molecule competitors (TYK2 inhibitors) are positioning to capture patients seeking non-injectable options.

• Combination strategies and treatment sequencing are being studied (e.g., rapid induction with one agent, maintenance with another).

• Biosimilar launches for older biologics (e.g., ustekinumab biosimilars) are increasing price competition and shifting treatment algorithms in some markets.

Top use cases

1. Moderate-to-severe plaque psoriasis — main use for biologics (IL-23/IL-17/TNF).

2. Psoriatic arthritis (PsA) — overlap population where some psoriasis drugs are also indicated (expands addressable population).

3. Mild disease / topical / oral therapies — older orals and topicals remain relevant for early-stage disease or patients not requiring biologics. 

Major challenges

• Proving long-term real-world outcomes and cost-effectiveness to payers; increasingly required for reimbursement.

• Market access & affordability in lower-income countries — biologic costs are a key constraint. 

• Rapidly evolving competitive space — several high-efficacy agents launched in a short window; companies must defend share with lifecycle strategies. 

Attractive opportunities

• Oral targeted agents (TYK2 and others) that are effective and easier to administer — significant commercial upside if safety profiles remain acceptable. 

• Emerging-market expansion and tiered pricing to broaden access and increase patient volumes. 

• Biosimilar development / manufacturing for older biologics — clear opportunity for firms that can produce cost-competitive biosimilars. 

Key factors for market expansion

• Continued clinical adoption of high-efficacy biologics and new orals. 

• Regulatory & reimbursement pathways that enable broader access (price negotiations, inclusion in formularies).

• Demonstration of real-world benefits (reduced hospitalizations, improved QoL) that justify higher per-patient spend. 

Sources (select highlights)

• Grand View Research — Psoriasis Drugs Market size & forecast (market anchor). 

• DrugDiscoveryTrends / industry summaries — Skyrizi 2024 sales (~$11.7B). Johnson & Johnson / Center for Biosimilars coverage — Stelara (ustekinumab) 2024 sales ~ $10.4B. 

• Novartis product sales tables — Cosentyx 2024 net sales USD 6,141M.

• Eli Lilly / press summaries — Taltz 2024 reported sales ~USD 3.2B.

• Amgen financial releases & GlobalData — Otezla quarterly/full-year sales context.

If you want, I can follow up immediately with one of these (I’ll fetch and extract the figures right away):
A) Pull product-level sales and year-by-year trends (2019–2024) for a shortlist of drugs (suggest: Skyrizi, Stelara, Cosentyx, Taltz, Otezla).
B) Produce a company revenue breakdown showing the portion of each company’s immunology/dermatology revenue attributable to psoriasis-indicated drugs (will require digging into investor decks and MD&A).
C) Build a market model (excel/table) that projects psoriasis drug revenues by class (IL-23, IL-17, TNF, TYK2, oral small molecules) to 2030 using a selected forecast house as baseline.

Which (A, B or C) would you like me to do next?